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ABSTRACT Classical pharmacokinetic descriptions do not adequately predict the dynamic and complex drug deposition
patterns that follow some novel delivery techniques, in part because they do not characterize binding within intact tissues in
sufficient detail. In this study, the binding site density of all the potential sites, the tissue-average dissociation constant, and
the fractional volume in which heparin can distribute in arterial tissues were measured by incubating tissue samples to
equilibrium in solutions containing a wide range of drug concentrations. An "equilibrium distribution curve" was constructed
by plotting the concentration of drug in each sample against the concentration in the corresponding bulk phase. The above
constants were determined by computationally fitting this curve to a model of drug distribution within tissues. The binding site
density was measured to be 4.2 AM, 2.5 ,uM, and 2.2 nM in porcine carotid media with intact and denuded endothelium, and
adventitia, respectively. The dissociation constant of heparin in these tissues was estimated to be 6.8 ,uM, 5.0 ,uM, and 8.1
nM, respectively. The fractional tissue volume of distribution was 0.61, 0.70, and 0.87, respectively. These values are
consistent with known properties of the heparin-arterial tissue interaction. Thus, this technique describes the cumulative
effects of binding of a compound to all of its potential binding sites, and will be essential to new detailed descriptions of drug
distribution.
INTRODUCTION
The hyperproliferative vascular response to injury is the
greatest limitation to the potential of mechanical revascu-
larization (Ip et al., 1990). Up to 50% of angioplasty pa-
tients must undergo a second procedure within 3-6 months
(Ellis et al., 1988), and now that immune rejection has been
partially treated with suppressants, more than half of the
heart transplants fail because of accelerated arteriosclerosis
(Ip et al., 1990). Much has been learned about the biology
of these diseases from tissue culture experiments, including
the principal cell types involved in this process and the role
of growth factors and receptors, glycoproteins, metallopro-
teases, selectins, etc. These studies have suggested classes
of compounds and specific agents that might be used to
combat these diseases, and yet none of these agents work in
the clinic. One of the limitations of extrapolating from tissue
culture data to clinical trials is the inadequacy of pharma-
cokinetic understanding and detailed modeling of the dis-
tribution for compounds. The binding of a single ligand to
a specific receptor describes events well in culture but is
clearly only a small part of all the physical interactions in an
intact tissue. These interactions include binding of drug to
nonspecific binding sites, idiosyncratic binding to different
tissue elements, differential functions of soluble and bound
drug, and gradients in concentration imposed by various
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means of administration to tissues. Heparin is a perfect
example of these phenomena. This polysaccharide is the
gold standard inhibitor of cultured vascular smooth muscle
cells (Castellot et al., 1981, 1985a, 1987), but if anything it
is an exacerbating agent in human disease (Ellis et al., 1989;
Lehmann et al., 1991). Recent data from our laboratory
demonstrated that its in vivo effects are remarkably sensi-
tive to the mode of administration (Edelman et al., 1990;
Rogers et al., 1993; Edelman and Karnovsky, 1994). Fur-
thermore, intermittent heparin dosing can exacerbate dis-
ease, whereas continuous administration will alleviate it
(Edelman and Karnovsky, 1994). Thus, a more mathemat-
ically rigorous pharmacokinetic model of drug distribution
is needed to correlate the mode of delivery with the biolog-
ical efficacy of drugs such as heparin.
Previously we examined the forces of heparin transport
within the blood vessel wall and measured the diffusivity of
heparin in different arterial layers (Lovich and Edelman,
1995). Detailed descriptions of drug deposition, however,
rely to an equal extent on drug binding to intact tissues. In
this study we present a novel and quantitative approach to
characterizing the binding of heparin to arterial tissues, in
terms of binding site density, tissue-average dissociation
constant, and fractional volume of tissue in which drug can
distribute. This technique attempts to fill the voids listed
above by quantifying both biologically active and nonspe-
cific binding, discriminating bound from soluble fractions
of drug in tissues, and allowing for drug concentration
gradients across tissues when combined with transport data
in future computational pharmacokinetic models. Although
validated here with heparin, the method is applicable to
many drugs and tissues.
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EQUILIBRIUM DISTRIBUTION MODEL
The equilibrium distribution technique measures the bind-
ing and distribution constants by incubating many samples
of tissues in solutions with a wide range of radiolabeled
drug concentrations and curve-fitting the resulting data to
the following model. The model is derived in general terms
and should be applicable to many compounds and tissues.
The total concentration of drug observed within a volume of
tissue (CT) is considered to be the superposition of soluble
(cs) and bound drug to both cell surface and extracellular
matrix binding sites (Cb):
CT Cs + Cb. ()
At very low drug concentrations, an increase in total con-
centration results in a linear increase in both soluble and
bound concentrations (Fig. 1). As binding sites saturate,
increases in the total concentration will be solely noted as
increases in the soluble concentration. In a unit volume of
tissue there are regions where soluble drug is excluded by
steric interactions. The fractional volume in which drug can
distribute (E) is given by:
Va
E VT (2)
where Va is the accessible space for drug distribution and VT
is the total tissue volume. Note that the convention used in
this work is that the drug concentrations CT, cs, and Cb are
defined as the moles of drug per unit total volume of tissue.
Thus, the moles of soluble drug per unit total volume of
tissue (cs) is related to the moles of soluble drug per unit
accessible volume (ca) by the fractional volume:
CS = ECa. (3)
The law of mass action defines the dissociation constant
(Kd) as the product of the drug concentration in the acces-
sible volume and the ratio of the molar densities of free (Bf)
and bound (Bb) binding sites:
CaBf
Kd = (4)
The number of binding sites is assumed to be conserved so
that the total binding site density (BT) can be expressed as
BT = Bf + Bb. (5)
Although in the context of the law of mass action these
binding site densities should be defined as moles of binding
sites per unit accessible volume, because the bound and free
densities are related as in Eq. 4, they can be and are defined
per unit total volume. By assuming a 1:1 bound ligand-to-
occupied binding site ratio:
Cb = Bb- (6)
By combining Eqs. 1, 3-6:
BTCa
CT = ECa + K+ (7)
Equilibrium distribution measurements
In these equilibrium distribution measurements, the concen-
tration of drug in the accessible volume (Ca) is established
by incubating the tissues in solutions containing radiola-
beled drug until equilibrium. The concentration of drug in
the accessible volume (ca), however, is not necessarily equal
to the external or bulk phase concentration (Cbulk) because of
potential charged partitioning. Thus:
Cbulk = KCa, (8)
where K is the partition coefficient of drug into the acces-
sible volume. Thus:
E CbUlkBT
CT = -Cbu +
K KKd + Cbulk' (9)
The dissociation constant and the partition coefficient are
combined into a modified dissociation constant reflecting
binding and charged association:
K = KKd. (10)
Similarly, a modified fractional volume of distribution re-
flecting sterical and charged effects can be defined:
E
~~( 1)
Thus:
CbulkBT
CT = ECbulk + K' + Cbulk (12)
Bulk Phase Concentration
FIGURE 1 Model of drug distribution through tissues at equilibrium.
The total concentration is the sum of the bound and soluble fractions. The
soluble concentration increases linearly with external or bulk phase con-
centration, whereas the bound fraction saturates.
Thus, the total concentration is a function of the concentra-
tion outside the tissue, and this nonlinear relationship de-
pends on the three binding and distribution constants, which
are specific to each drug and tissue.
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Curve fitting and initial estimates
A commercially available nonlinear least-squares Leven-
berg-Marquardt algorithm including a Pearson minimiza-
tion (TableCurve 2D, Jandel Scientific, San Rafael, CA)
was used to fit the data and determine the binding and
distribution constants (E', BT, and K'). Because the bulk
phase concentration data must span many orders of magni-
tude, a fit to Eq. 12 would preferentially weight the data
taken at the highest bulk phase concentrations. The inherent
weighting can be distributed over all of the data points by
fitting the logarithm of the measured total concentration (CT)
to the following equation:
ln(cT) ln( cbulk + CbukBT ) (13)Cbl
K' +Cbulk/
Nonlinear least-squares algorithms are sensitive to the ini-
tial estimates of the unknown constants (Press et al., 1986).
The following approximate method for determining ', BT,
and K' from the equilibrium distribution curve is used to
provide the initial estimates for the curve fit. Consider an
idealized equilibrium distribution curve that is the sum of
the bound and soluble drug (Fig. 1). A least-squares esti-
mate of the slope (E') at high bulk phase concentrations
allows the soluble component of the data (E'Cbulk) to be
subtracted from the total concentration data, reducing Eq.
12 to
CbulkBT
Cb =K + Cu (14)
The resulting plateau can be considered equivalent to the
total number of binding sites. The average dissociation
constant can be estimated as the bulk phase concentration at
which half of the binding sites are occupied.
The reliability of the commercial software was assessed
by writing an alternative curve-fitting program utilizing a
Nelder-Meade function-minimization routine (Matlab,
Math Works, Natick, MA). All of the constants computed
by the former algorithm differed maximally from the later
by 8%, thus validating the former.
Bound and soluble fractions
The equilibrium distribution method also allows for the total
concentration measurement (CT) to be resolved into bound
and soluble components. By combining Eqs. 3, 7, 10, and
11:
Cs =
CT- BT- K'E' + 1(CT-BT-K'e') +4CT
2
(I1J)
The distinction between bound and soluble drug is impor-
tant. Although soluble drug binds to active receptors and
mediates extracellular signaling events, nonspecific binding
sites play a distinct role, as they sequester drug in the
vicinity of active receptors (Nugent and Edelman, 1992;
Edelman et al., 1993). Furthermore, in terms of drug distri-
bution and pharmacokinetics, only the soluble fraction of
drug is available to diffuse or convect through a tissue,
whereas potential binding sites tend to impede the move-
ment of drug.
EXPERIMENTAL METHODS
The equilibrium distribution method described above was used to deter-
mine the binding and distribution constants (BT, k', and E') for heparin in
porcine carotid media with endothelium intact and after endothelial denu-
dation, and in the adventitia. Porcine carotid arteries were explanted and
stored on ice for no more than 2 h. The adventitia was stripped from the
media, and both were temporarily stored in 2% penicillin-streptomycin
(Gibco, Gaithersburg, MD) in sterile phosphate buffered saline. The en-
dothelium of some of these arteries were denuded with three passes of an
inflated 3 French embolectomy catheter (Baxter, McGaw Park, IL)
(Clowes et al., 1983). Arteries were cut into 10-40-mg pieces and incu-
bated in Dulbecco's modified Eagle's medium (Gibco) with 10% fetal
bovine serum (Gibco) and 2% penicillin-streptomycin, with [3H]heparin
(Dupont-NEN, Wilmington, DE) concentrations ranging from approxi-
mately 100 pM to 0.2 mM. All incubations were performed in 2 ml of
culture medium and were carried out until equilibrium, which was achieved
when the time rate of increase of drug concentration in the tissue reached
zero. After incubation, the arterial specimens were blotted on dry towels,
weighed wet, solubilized, and scintillation counted. At least four pieces of
each type of tissue were incubated at each bulk phase concentration (cbulk).
Bulk phase heparin concentration measurements were made at the end of
the incubations and were the average of three 50-,ul samples from each
culture well. These equilibrium distribution measurements were repeated
twice for each tissue type, using different batches of reagents. Histological
frozen sections were taken from representative arteries for morphological
evaluation.
Prior to the above experiments, the time course of heparin equilibration
was quantified in samples of porcine carotid media with endothelium by
incubating in a bulk phase concentration of 0.15 mg/ml (Fig. 2). Although
vascular cells and interstitial molecules may continue to exchange drug
with the bulk phase, these data show that heparin reaches equilibrium with
the tissue as a whole well within 24 h. All subsequent incubations were
therefore carried out for this duration. In separate experiments, the density
of fresh porcine carotid media was measured using a micro-graduated
cylinder and an analytical balance. The resulting density of 0.983 ± 0.024
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FIGURE 2 Total concentration of porcine carotid media over time when
incubated in 0.15 mg/ml heparin. Equilibrium is achieved in less than 24 h
(average ± standard error, n = 4).
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g/ml (n = 5, + standard deviation) was used to convert wet weight to
volume for calculations of total drug concentration in tissue.
VERIFICATION OF THE EQUILIBRIUM
DISTRIBUTION METHOD
Equilibrium distribution data are shown for arterial media
with intact and denuded endothelium and adventitia (Fig. 3).
Each point shown represents the average (± standard error)
of at least four total concentration measurements on samples
of tissue from the same culture well and three measurements
of the bulk phase concentration in that well. Note that the
error bars are present but unappreciable on the logarithmic
scale. For each tissue type, initial estimates of the fractional
volume of tissue in which drug can distribute (e') were
determined through linear regression of the high bulk phase
concentration data (cbulk > 10-5 M; Table 1). Fig. 4 shows
all of these data after the subtraction of the soluble fraction
of drug (E'Cbulk). For arterial media with intact and denuded
endothelium, initial estimates of the binding site density
(BT) were estimated as the plateau of these curves. The
dissociation constant of the average binding site (K') was
estimated as the bulk phase concentration where half of the
binding sites were saturated. The Levenberg-Marquardt
curve-fit algorithm converged to the solutions shown (Table
2) when the initial estimates (Table 1) were used and when
these initial estimates were perturbed up or down by two
orders of magnitude for BT and K', and by 0.2 for E', for
arterial media with intact and denuded endothelium. This
curve-fit software also calculated standard errors for each
binding and distribution constant. These fits were further
assessed by computing best-fit curves for the experimental
data and the computed bound concentrations using Eqs. 12
and 14, respectively (Figs. 3 and 4, solid lines). It was not
possible to obtain initial estimates of BT and K' for the
adventitia because the bound concentration spread about
zero after the subtraction of the linear soluble component
(Fig. 4 c). This indicated that the binding site density in this
tissue was lower than the scatter in the data at high bulk
phase concentrations. Despite this, the curve-fit algorithm
converged on binding constants for the adventitia (Table 2)
that were consistent over a wide range of assumed initial
estimates.
The equilibrium distribution analysis for heparin within
arterial tissues predicts observed heparin-vascular tissue
interactions. The fractional volume of tissue in which a drug
can distribute (e') is highest in the adventitia and increases
in the arterial media after balloon denuding injury (Table 2),
reflecting the loose architecture and high content of con-
nective tissues of the former (Murata et al., 1986; Haas et
al., 1991) and the role of structural damage in the latter. The
analysis also shows that the concentration of binding sites
(BT) in the arterial wall is larger with intact endothelium,
consistent with many reports that this monolayer binds
heparin (Glimelius et al., 1978; Barzu et al., 1985, 1986;
Vannucchi et al., 1986; Psuja, 1987; Hiebert and McDuffie,
1989). In addition, cultured endothelial cells possess nearly
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FIGURE 3 Measured equilibrium distribution curves for heparin within
(a) arterial media with endothelium, (b) denuded media, and (c) adventitia
(average ± standard error, n > 4). Solid lines are generated from the curve
fit binding and distribution constants (E', BT, and K') shown in Table 2 and
Eq. 12.
100-fold more heparin binding sites than cultured vascular
smooth muscle cells (Castellot et al., 1985b; Psuja, 1987).
Thus, it is plausible that the presence of the endothelium
may nearly double the number of heparin binding sites on a
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TABLE I Sample binding and distribution constants*
E' BT (MM) K' (KM)
Arterial media with intact endothelium 0.60 4 12
Arterial media with denuded endothelium 0.63 8 10
Adventitia 0.78
*Determined by 1) finding the slope (E') of the equilibrium distribution
data (Fig. 3) for Cbulk > 10-5 M; 2) subtracting E'Cbul from the data and
replotting (Fig. 4); 3) approximating BT as the plateau of the subsequent
data; and 4) approximating K' as cbul at B112. Note that BT and K' were
too low to be estimated in the adventitia.
large 250-,um-thick artery as we report. The dissociation
constant of the average binding site (K') of the arterial
media, assuming a partition coefficient of 1, is three orders
of magnitude higher than for growth-arrested smooth mus-
cle cells and basic fibroblast growth factor (Castellot et al.,
1985b; San Antonio et al., 1993), and about one to two
orders of magnitude higher than laminin, fibronectin, and
type I collagen (San Antonio et al., 1993), indicating that
much of the binding is to arterial elements with even lower
affinity. The dissociation constant (K') of the arterial media
is much higher than that of the adventitia, indicating that
although there are far fewer binding sites in the latter, they
are of much higher affinity. This may be explained by the
large concentration of type I collagen in the adventitia
(Murata et al., 1986; Haas et al., 1991), whose affinity for
heparin is about the same as the values we report here for
the adventitia (San Antonio et al., 1993), and the relative
scarcity of cells and hence cell surface binding sites. These
trends are consistent with known properties of the heparin-
arterial tissue interaction and help validate the equilibrium
distribution technique.
DISCUSSION
We sought to create a quantitative description of how drugs
distribute and bind to intact tissues, with the hope of incor-
porating these findings into new detailed pharmacokinetic
models. This new equilibrium distribution analysis quanti-
fies drug binding to all its potential binding sites, distin-
guishes between soluble and bound components of drug
concentration, and allows for large gradients in deposited
drug. This was accomplished by incubating many samples
of tissue in solutions containing a wide range of drug
concentrations, measuring the corresponding tissue concen-
trations, and computationally fitting these data to a model of
drug distribution and binding. In this way, the binding site
density, dissociation constant of the average binding site,
and fractional volume of drug distribution were measured
for heparin in arterial tissues, and these results were used to
validate the technique.
Two methods of determining the binding and distribution
constants (E', BT, and K') from an equilibrium distribution
curve have been described. The first requires a linear re-
gression of the data, algebra, and visual inspection. Al-
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FIGURE 4 Bound concentration of drug in the tissue (Cb) for (a) arterial
media with endothelium, (b) denuded media, and (c) adventitia, determined
by subtracting the soluble (cs) fraction from the total concentration (CT).
The plateau corresponds to the binding site density (BT) (average ± standard
error, n > 4). Note that low signal-to-noise ratios prevented the demonstration
of the binding site density in the adventitia. Solid lines are generated from the
curve fit binding constants (BT and K') shown in Table 2 and Eq. 14.
though this method is relatively simple, it affords no assess-
ment of the "goodness of fit" or statistical measure of
accuracy. In addition, errors in estimating E' are carried
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TABLE 2 Binding and distribution constants determined with
a nonlinear least-squares Levenberg-Marqutardt algorithm
El BT K'
Arterial media with
intact endothelium 0.61 ± 0.03 4.2 ± 1.7 (,uM) 6.8 ± 2.5 (,uLM)
Arterial media with
denuded endothelium 0.70 ± 0.03 2.5 ± 1.1 (,uM) 5.0 ± 2.1 (,uM)
Adventitia 0.87 ± 0.02 2.2 ± 1.3 (nM) 8.1 ± 5.7 (nM)
Values ± standard error.
through to BT and K'. The second curve-fitting technique
requires the use of more sophisticated computational algo-
rithms to arrive at estimations of the binding and distribu-
tion constants. A commercially available software package
is used that computes the standard error for each measured
constant. The former method, however, provides the re-
quired initial estimates used in the latter method.
Although the tissue concentration data are repeatable
(Fig. 3), some of the standard errors are relatively high
(Table 2). This results in part from the dependence of
these particular constants on the subtle convexity of the
equilibrium distribution curve, so that small concentra-
tion measurement errors create uncertainty. Furthermore,
if the scatter in the data is greater than the binding site
density, as was encountered with the adventitia, after the
subtraction of the soluble component the bound concen-
tration data spread about zero (Fig. 4 c). Thus, a low
signal-to-noise ratio limits the accuracy of the technique
to drug-tissue interactions with a relatively large number
of binding sites.
The derivation of the equilibrium distribution method
assumed that there was a one-to-one stochiometric rela-
tionship between occupied binding sites and bound drug.
Although this may be valid for many drugs, for some
compounds a single ligand may be able to simultaneously
bind several sites, thus limiting the applicability of the
law of mass action. This phenomenon may occur in some
of the heparin binding sites in arterial tissues. In addition,
the partition coefficient (K) remains unquantified, as it is
difficult to measure in complicated structures such as
arterial tissues; however, it is expected to be about 1.
Despite these possible sources of artifact, these binding
constants empirically reflect the drug-tissue interaction
and allow for the realistic distinction between bound and
soluble drug.
SUMMARY
The equilibrium distribution measurements and subsequent
numerical analysis are a useful method of describing the
binding of compounds to tissues, not just individual binding
sites, and should be applicable to many drug-tissue interac-
tions. Each set of measurements determines the fractional
volume of tissue available for drug distribution, binding site
density, and affinity of the average binding site. In addition,
these constants allow the determination of the bound and
soluble fractions of drug from tissue concentration measure-
ments. This information is important as it not only allows
for the description of the effects of binding on deposition,
but is a prime determinant of the kinetic concentrations
produced by novel drug delivery systems.
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